Fusion protein · Immune activation, directed at programmed cell death protein 1 (PDCD1) and interleukin-15 receptor (IL15RA) · developed by Sanofi
Daxokafusp alfa is a fusion protein with an antibody moiety that binds PD-1 and blocks its inhibitory signaling, linked to a mutein of the cytokine IL-15 that activates IL-15 receptor signaling. It is being studied in non-small cell lung cancer refractory to immune checkpoint inhibitors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07133425 | Phase 2 | Non-Small Cell Lung Cancer | Recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ICI-refractoryNon-Small Cell Lung Cancer
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →